Diligence memo · auto-generated · as of July 2, 2026
Synthego Corp
Synthego Corp looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Synthego Corp operates in Biotechnology, based in REDWOOD CITY.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Synthego Corp has raised $156M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $106M on 2018-10-09.
Most recent recorded round closed around 2018-10-09.
Valuation (modeled)modeled
Provath models Synthego Corp at approximately $4.4B (range $482M–$9.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Series D+ Biotechnology companies in 2016–2018 (13 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 7.7 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 95% of Biotechnology peers (4293 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Guardant Health, Inc., Humacyte, Inc., Atreca, Inc., Semma Therapeutics, Inc., Braeburn Pharmaceuticals, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.